Sanofi and Regeneron announce new, detailed data from positive sarilumab Phase 3 rheumatoid arthritis trial at EULAR
12 June 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. presented positive results from a phase 3 trial of investigational drug sarilumab in rheumatoid arthritis patients who were inadequate responders to methotrexate therapy...